The role of mTOR pathway as target for treatment in adrenocortical cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Adrenocortical carcinomas (ACCs) are rare endocrine tumors with limited therapeutic options.
• The mammalian target of rapamycin (mTOR) pathway is crucial for cell signaling and implicated in various cancers.
• Targeting the mTOR pathway presents a potential strategy for novel ACC treatments.

Purpose of the Study:

• To review the expression of mTOR pathway components in ACCs.
• To summarize the efficacy of mTOR inhibitors in preclinical ACC models.
• To evaluate early clinical experiences with mTOR inhibitors in ACC patients.

Main Methods:

• Literature review of studies on mTOR pathway expression in ACCs.
• Analysis of preclinical data on mTOR inhibitors (sirolimus, temsirolimus, everolimus) in ACC models.
• Summary of early clinical trial results for mTOR inhibitors in ACC.

Main Results:

• The mTOR pathway is frequently dysregulated in ACCs.
• mTOR inhibitors demonstrate anti-tumor effects in preclinical ACC models, both as monotherapy and in combination.
• Early clinical data suggest a potential role for mTOR inhibitors, but further research is necessary.

Conclusions:

• The mTOR pathway is a promising therapeutic target for adrenocortical carcinomas.
• Further clinical investigation is required to establish the optimal use of mTOR inhibitors, alone or in combination, for ACC treatment.